From the publishers of JADPRO

Myeloproliferative Neoplasms Resource Center

Advertisement

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis

This review article details the clinical trials that led to the approval of ruxolitinib and fedratinib for the treatment of myelofibrosis, and provides data on JAK inhibitors momelotinib and pacritinib currently being studied in this disease state.

Therapeutic Advances in Hematology
Advertisement
News & Literature Highlights
Advertisement
Advertisement